Newly discovered ‘encrypted peptides’ with antibiotic properties
A new study reports three distinct proteins in human plasma that have naturally occurring antibiotic properties. Global public health officials are concerned about the r
Decade-long remission after CAR T cell therapy
Two patients represent longest-known CAR T cell response to date, providing insight into treatment effect and outcomes.
The Center for Breakthrough Medicines and Penn partner in the manufacturing of gene therapies
Penn’s Innovation in Process Science combines with CBM manufacturing capability to develop large-scale gene therapy manufacturing capacity, testing, and analytics
Halting Progress and Happy Accidents: How mRNA vaccines were made
A New York Times feature on the history, research, challenges, and timeline to make the COVID-19 mRNA vaccines.
Moderna forms oncology collaboration with Carisma Therapeutics
Moderna will collaborate with Penn spinout Carisma Therapeutics to discover, develop and commercialize in-vivo engineered chimeric antigen receptor monocyte therapeutics for the treatment of cancer.
From foundational discoveries to profound impact
Without the mRNA technology foundation laid by Karikó and Weissman, the Pfizer/BioNTech and Moderna vaccines being deployed across the world would not exist.
Technology used in mRNA COVID vaccines offers hope for treatment of millions with heart disease, study suggests
Combining technologies that proved hugely success against cancer and in COVID-19 vaccines, researchers at Penn have shown they can effectively treat a leading cause of heart disease.
Vaccine-like mRNA injection can be used to make CAR T cells in the body
The researchers, whose work is published in Science, demonstrated the new approach with an mRNA preparation that reprograms T cells—a powerful type of immune cell—to attack heart fibroblast cells.
Katalin Karikó, PhD, featured on the cover of Newsweek as one of America’s Greatest Disruptors
She was described as being one of the 50 visionaries whose career-long actions have had far-reaching impact.
Scout Bio licenses new Penn technology to help develop gene therapies for pets
Scout Bio, a Philadelphia company developing gene therapies for animal health, has licensed a new kind of technology from the Penn’s gene therapy program.